Cargando…

Brain metastases free survival differs between breast cancer subtypes

BACKGROUND: Brain metastases (BM) are frequently diagnosed in patients with HER-2-positive metastatic breast cancer; in addition, an increasing incidence was reported for triple-negative tumours. We aimed to compare brain metastases free survival (BMFS) of breast cancer subtypes in patients treated...

Descripción completa

Detalles Bibliográficos
Autores principales:	Berghoff, A, Bago-Horvath, Z, De Vries, C, Dubsky, P, Pluschnig, U, Rudas, M, Rottenfusser, A, Knauer, M, Eiter, H, Fitzal, F, Dieckmann, K, Mader, R M, Gnant, M, Zielinski, C C, Steger, G G, Preusser, M, Bartsch, R
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2012
Materias:	Clinical Studies
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3273356/ https://www.ncbi.nlm.nih.gov/pubmed/22233926 http://dx.doi.org/10.1038/bjc.2011.597

Ejemplares similares

Impact of anti-HER2 therapy on overall survival in HER2-overexpressing breast cancer patients with brain metastases
por: Bartsch, R, et al.
Publicado: (2012)

Prognostic impact of breast cancer subtypes in elderly patients
por: Bergen, E. S., et al.
Publicado: (2016)

Predicting for activity of second-line trastuzumab-based therapy in her2-positive advanced breast cancer
por: Bartsch, Rupert, et al.
Publicado: (2009)

The multigene signature MammaPrint impacts on multidisciplinary team decisions in ER(+), HER2(−) early breast cancer
por: Exner, R, et al.
Publicado: (2014)

Brain-only metastatic breast cancer is a distinct clinical entity characterised by favourable median overall survival time and a high rate of long-term survivors
por: Berghoff, A S, et al.
Publicado: (2012)

Brain metastases as first manifestation of advanced cancer: exploratory analysis of 459 patients at a tertiary care center
por: Füreder, L. M., et al.
Publicado: (2018)

Independent validation of stromal uPA in ABCSG-08: Level 1b evidence for the prognostic value of uPA immunohistochemistry
por: Singer, C.F., et al.
Publicado: (2022)

PAM-50 predicts local recurrence after breast cancer surgery in postmenopausal patients with ER+/HER2– disease: results from 1204 patients in the randomized ABCSG-8 trial
por: Fitzal, F, et al.
Publicado: (2021)

The genomic expression test EndoPredict is a prognostic tool for identifying risk of local recurrence in postmenopausal endocrine receptor-positive, her2neu-negative breast cancer patients randomised within the prospective ABCSG 8 trial
por: Fitzal, F, et al.
Publicado: (2015)

Favourable outcome of patients with breast cancer brain metastases treated with dual HER2 blockade of trastuzumab and pertuzumab
por: Bergen, Elisabeth Sophie, et al.
Publicado: (2021)

Factors influencing agreement of breast cancer luminal molecular subtype by Ki67 labeling index between core needle biopsy and surgical resection specimens
por: Tendl-Schulz, Kristina A., et al.
Publicado: (2020)

ESR1, PGR, ERBB2, and MKi67 mRNA expression in postmenopausal women with hormone receptor-positive early breast cancer: results from ABCSG Trial 6
por: Filipits, M., et al.
Publicado: (2021)

Descriptive statistical analysis of a real life cohort of 2419 patients with brain metastases of solid cancers
por: Berghoff, Anna S, et al.
Publicado: (2016)

Indocyanine Green Video Angiography Predicts Outcome of Extravasation Injuries
por: Haslik, Werner, et al.
Publicado: (2014)

Expression of thymidine phosphorylase in peripheral blood cells of breast cancer patients is not increased by paclitaxel
por: Bartsch, Rupert, et al.
Publicado: (2007)

Primary tumor side is associated with prognosis of colorectal cancer patients with brain metastases
por: Bergen, E.S., et al.
Publicado: (2021)

A clinical validation study of MammaPrint in hormone receptor-positive breast cancer from the Austrian Breast and Colorectal Cancer Study Group 8 (ABCSG-8) biomarker cohort
por: Dubsky, P., et al.
Publicado: (2020)

The predictive impact of body mass index on the efficacy of extended adjuvant endocrine treatment with anastrozole in postmenopausal patients with breast cancer: an analysis of the randomised ABCSG-6a trial
por: Gnant, M, et al.
Publicado: (2013)

Aromatase inhibitors with or without gonadotropin-releasing hormone analogue in metastatic male breast cancer: a case series
por: Zagouri, F, et al.
Publicado: (2013)

Survival prediction using temporal muscle thickness measurements on cranial magnetic resonance images in patients with newly diagnosed brain metastases
por: Furtner, Julia, et al.
Publicado: (2017)

Introducing pro and con discussions in ESMO Open—Cancer Horizons
por: Zielinski, C., et al.
Publicado: (2022)

Prognostic value of monitoring tumour markers CA 15-3 and CEA during fulvestrant treatment
por: Bartsch, Rupert, et al.
Publicado: (2006)

Primary surgery versus no surgery in synchronous metastatic breast cancer: patient-reported quality-of-life outcomes of the prospective randomized multicenter ABCSG-28 Posytive Trial
por: Bjelic-Radisic, V., et al.
Publicado: (2020)

New developments in brain metastases
por: Berghoff, Anna S., et al.
Publicado: (2018)

Impact of Surgical Margins in Breast Cancer After Preoperative Systemic Chemotherapy on Local Recurrence and Survival
por: Wimmer, K., et al.
Publicado: (2019)

Anti-angiogenic therapies in brain metastases
por: Berghoff, Anna S., et al.
Publicado: (2018)

Targeted Therapies for Melanoma Brain Metastases
por: Berghoff, Anna S., et al.
Publicado: (2017)

Tumor mutational burden and immune infiltrates in renal cell carcinoma and matched brain metastases
por: Steindl, A., et al.
Publicado: (2021)

Analysis of trastuzumab and chemotherapy in advanced breast cancer after the failure of at least one earlier combination: An observational study
por: Bartsch, Rupert, et al.
Publicado: (2006)

Differential immunomodulatory effects of epirubicin/cyclophosphamide and docetaxel in breast cancer patients
por: Wimmer, Kerstin, et al.
Publicado: (2023)

Impact of body mass index on estradiol depletion by aromatase inhibitors in postmenopausal women with early breast cancer
por: Pfeiler, G, et al.
Publicado: (2013)

Modulation of plasma complement by the initial dose of epirubicin/docetaxel therapy in breast cancer and its predictive value
por: Michlmayr, A, et al.
Publicado: (2010)

Tissue distribution of epirubicin after severe extravasation in humans
por: Nedomansky, Jakob, et al.
Publicado: (2021)

Conventional versus reverse sequence of neoadjuvant epirubicin/cyclophosphamide and docetaxel: sequencing results from ABCSG-34
por: Bartsch, Rupert, et al.
Publicado: (2021)

Extravasation emergencies: state-of-the-art management and progress in clinical research
por: Pluschnig, Ursula, et al.
Publicado: (2016)

Efficacy of tamoxifen±aminoglutethimide in normal weight and overweight postmenopausal patients with hormone receptor-positive breast cancer: an analysis of 1509 patients of the ABCSG-06 trial
por: Pfeiler, G, et al.
Publicado: (2013)

The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2− breast cancer patients
por: Dubsky, P, et al.
Publicado: (2013)

Systemic inflammation scores correlate with survival prognosis in patients with newly diagnosed brain metastases
por: Starzer, Angelika M., et al.
Publicado: (2021)

Single-agent pegylated liposomal doxorubicin (PLD) in the treatment of metastatic breast cancer: results of an Austrian observational trial
por: Fiegl, Michael, et al.
Publicado: (2011)

Trastuzumab deruxtecan in HER2-positive breast cancer with brain metastases: a single-arm, phase 2 trial
por: Bartsch, Rupert, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_0gg4hn4qn2lnmf0o039ek950b3